New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2013
04:55 EDTAZN, AZN, BAYRY, BAYRY, DB, DB, TEVA, TEVA, NVS, NVS, RHHBY, RHHBY, PFE, PFEFinancial Times to hold a conference
Global Pharmaceutical & Biotech Conference is being held in London, England on December 3-4.
News For AZN;BAYRY;DB;TEVA;NVS;RHHBY;PFE From The Last 14 Days
Check below for free stories on AZN;BAYRY;DB;TEVA;NVS;RHHBY;PFE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 15, 2014
12:26 EDTTEVATeva announces launch of generic Lunesta tablets in U.S.
Subscribe for More Information
09:02 EDTRHHBYRoche confirms FY outlook for low-to mid-single digit growth in sales
Subscribe for More Information
09:01 EDTRHHBYRoche reports Q1 sales CHF11.496B vs. CHF11.589B a year ago
Roche reported Q1 group sales rose 5% at constant exchange rates and fell 1% in Swiss francs compared to the prior year. Pharma sales were up 4%, with continued growth of Avastin, MabThera/Rituxan, Actemra/RoActemra and Herceptin compensating for expected decline in Xeloda sales, while Diagnostics division sales were up 7%. Roche CEO Severin Schwan said: “Both the Pharma and Diagnostics Divisions posted solid growth in the first quarter. I am particularly pleased with the strong uptake of our recently launched medicines Perjeta and Kadcyla for HER2-positive breast cancer."
08:23 EDTRHHBYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:19 EDTRHHBY, AZNLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:04 EDTPFEWuXi PharmaTech names Steve Yang as COO and Executive VP
Subscribe for More Information
07:35 EDTNVSAlnylam outlook not affected by Novartis decision, says JMP Securities
Subscribe for More Information
07:22 EDTNVSNovartis to Shire said to mull offers for ThromboGenics, Bloomberg says
Subscribe for More Information
06:36 EDTNVSRanbaxy inspection failures add $900M to heart drug costs, Bloomberg says
A gap in U.S. patent law has kept cheap copies of Novartis' (NVS) heart drug Diovan off the market for 18 months, which has cost U.S. consumers and insurers as much as $900M in possible savings, reported Bloomberg. Ranbaxy (RBXLY) is the only company permitted to sell a generic version of Diovan, and hasn’t been able to manufacture and market them after four factories it runs in India failed U.S. inspections. Reference Link
06:32 EDTPFE, RHHBY, AZN, NVSPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
14:42 EDTNVSAlnylam slips after Novartis reportedly cuts back RNAi development
Subscribe for More Information
11:48 EDTNVSNovartis significantly reducing RNAi development efforts, FierceBiotech says
Subscribe for More Information
09:05 EDTPFEGlycoMimetics presents GMI-1070 data
Subscribe for More Information
April 11, 2014
07:47 EDTDBDeutsche granted dismissal of FHFA suit, Reuters says
Subscribe for More Information
07:19 EDTPFEAcura Pharma to host conference call
Subscribe for More Information
April 10, 2014
11:42 EDTRHHBYReport claims Tamiflu, Relenza do little to prevent the spread of flu
Subscribe for More Information
08:26 EDTDBDeutsche looks for shareholder approval for upped bonuses, Reuters says
Deutsche Bank will ask shareholders to approve increasing limits on executive bonuses for FY14 as required by new European regulations, according to Reuters, citing an agenda for the bank's annual shareholder meeting. Reference Link
07:24 EDTBAYRYInternational Society for Heart & Lung Transplantation to hold annual meeting
Subscribe for More Information
07:11 EDTDBDeutsche said to find inappropriate communication in FX case, Bloomberg says
Deutsche Bank laid-off a London-based currency saleswoman last month for improper communication with the Monetary Authority of Singapore, according to Bloomberg, citing a person familiar with the matter. In an emailed statement, Deutsche Bank said it had received requests for information from regulators probing currency trading and is cooperating with them. Reference Link
06:17 EDTPFEAcura Pharma announces return of product rights from Pfizer
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use